Logo image of NTRB

NUTRIBAND INC (NTRB) Stock Fundamental Analysis

NASDAQ:NTRB - US67092M2089 - Common Stock

6.405 USD
-0.03 (-0.47%)
Last: 8/25/2025, 8:00:02 PM
Fundamental Rating

4

NTRB gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 193 industry peers in the Pharmaceuticals industry. The financial health of NTRB is average, but there are quite some concerns on its profitability. NTRB is growing strongly while it is still valued neutral. This is a good combination!


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year NTRB has reported negative net income.
In the past year NTRB has reported a negative cash flow from operations.
NTRB had negative earnings in each of the past 5 years.
In the past 5 years NTRB always reported negative operating cash flow.
NTRB Yearly Net Income VS EBIT VS OCF VS FCFNTRB Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -2M -4M -6M -8M -10M

1.2 Ratios

The Return On Assets of NTRB (-162.11%) is worse than 84.97% of its industry peers.
With a Return On Equity value of -195.43%, NTRB is not doing good in the industry: 68.91% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -162.11%
ROE -195.43%
ROIC N/A
ROA(3y)-86.9%
ROA(5y)-68.06%
ROE(3y)-100.18%
ROE(5y)-79.11%
ROIC(3y)N/A
ROIC(5y)N/A
NTRB Yearly ROA, ROE, ROICNTRB Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -500 -1K -1.5K -2K

1.3 Margins

Looking at the Gross Margin, with a value of 34.63%, NTRB is in line with its industry, outperforming 58.03% of the companies in the same industry.
In the last couple of years the Gross Margin of NTRB has remained more or less at the same level.
NTRB does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 34.63%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.68%
GM growth 5YN/A
NTRB Yearly Profit, Operating, Gross MarginsNTRB Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -200 -400 -600 -800 -1K

More info and screens

5

2. Health

2.1 Basic Checks

NTRB does not have a ROIC to compare to the WACC, probably because it is not profitable.
NTRB has more shares outstanding than it did 1 year ago.
NTRB has more shares outstanding than it did 5 years ago.
The debt/assets ratio for NTRB has been reduced compared to a year ago.
NTRB Yearly Shares OutstandingNTRB Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2M 4M 6M 8M 10M
NTRB Yearly Total Debt VS Total AssetsNTRB Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2M 4M 6M 8M 10M

2.2 Solvency

NTRB has an Altman-Z score of 29.33. This indicates that NTRB is financially healthy and has little risk of bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 29.33, NTRB belongs to the top of the industry, outperforming 96.37% of the companies in the same industry.
A Debt/Equity ratio of 0.01 indicates that NTRB is not too dependend on debt financing.
The Debt to Equity ratio of NTRB (0.01) is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Altman-Z 29.33
ROIC/WACCN/A
WACC9.95%
NTRB Yearly LT Debt VS Equity VS FCFNTRB Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 5M 10M

2.3 Liquidity

NTRB has a Current Ratio of 3.71. This indicates that NTRB is financially healthy and has no problem in meeting its short term obligations.
NTRB's Current ratio of 3.71 is fine compared to the rest of the industry. NTRB outperforms 62.18% of its industry peers.
NTRB has a Quick Ratio of 3.47. This indicates that NTRB is financially healthy and has no problem in meeting its short term obligations.
NTRB has a better Quick ratio (3.47) than 62.69% of its industry peers.
Industry RankSector Rank
Current Ratio 3.71
Quick Ratio 3.47
NTRB Yearly Current Assets VS Current LiabilitesNTRB Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 1M 2M 3M 4M 5M

More info and screens

7

3. Growth

3.1 Past

The earnings per share for NTRB have decreased strongly by -17.68% in the last year.
NTRB shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 18.92%.
NTRB shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 41.99% yearly.
EPS 1Y (TTM)-17.68%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%39.77%
Revenue 1Y (TTM)18.92%
Revenue growth 3Y14.58%
Revenue growth 5Y41.99%
Sales Q2Q%63.39%

3.2 Future

The Earnings Per Share is expected to grow by 100.83% on average over the next years. This is a very strong growth
NTRB is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 334.01% yearly.
EPS Next Y6.67%
EPS Next 2Y110.16%
EPS Next 3Y100.83%
EPS Next 5YN/A
Revenue Next Year528.03%
Revenue Next 2Y557.52%
Revenue Next 3Y334.01%
Revenue Next 5YN/A

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
NTRB Yearly Revenue VS EstimatesNTRB Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 50M 100M 150M
NTRB Yearly EPS VS EstimatesNTRB Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 0 1 2 3

More info and screens

4

4. Valuation

4.1 Price/Earnings Ratio

NTRB reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
A Price/Forward Earnings ratio of 4.33 indicates a rather cheap valuation of NTRB.
Compared to the rest of the industry, the Price/Forward Earnings ratio of NTRB indicates a rather cheap valuation: NTRB is cheaper than 96.89% of the companies listed in the same industry.
Compared to an average S&P500 Price/Forward Earnings ratio of 22.63, NTRB is valued rather cheaply.
Industry RankSector Rank
PE N/A
Fwd PE 4.33
NTRB Price Earnings VS Forward Price EarningsNTRB Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
NTRB Per share dataNTRB EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as NTRB's earnings are expected to grow with 100.83% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y110.16%
EPS Next 3Y100.83%

More info and screens

0

5. Dividend

5.1 Amount

NTRB does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

NUTRIBAND INC

NASDAQ:NTRB (8/25/2025, 8:00:02 PM)

6.405

-0.03 (-0.47%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)05-30 2025-05-30/amc
Earnings (Next)09-01 2025-09-01
Inst Owners3.05%
Inst Owner Change3.88%
Ins Owners60.16%
Ins Owner Change0%
Market Cap71.42M
Analysts82.86
Price Target15.3 (138.88%)
Short Float %2.47%
Short Ratio0.46
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-145.1%
Min EPS beat(2)-316.67%
Max EPS beat(2)26.47%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-6.41%
Min Revenue beat(2)-11.21%
Max Revenue beat(2)-1.6%
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)15.38%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-6.25%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-7.24%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-1.6%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 4.33
P/S 29.78
P/FCF N/A
P/OCF N/A
P/B 13.99
P/tB 22.76
EV/EBITDA N/A
EPS(TTM)-0.9
EYN/A
EPS(NY)1.48
Fwd EY23.09%
FCF(TTM)-0.47
FCFYN/A
OCF(TTM)-0.46
OCFYN/A
SpS0.22
BVpS0.46
TBVpS0.28
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -162.11%
ROE -195.43%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 34.63%
FCFM N/A
ROA(3y)-86.9%
ROA(5y)-68.06%
ROE(3y)-100.18%
ROE(5y)-79.11%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.68%
GM growth 5YN/A
F-Score4
Asset Turnover0.39
Health
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 33.31%
Cap/Sales 3.8%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.71
Quick Ratio 3.47
Altman-Z 29.33
F-Score4
WACC9.95%
ROIC/WACCN/A
Cap/Depr(3y)24.77%
Cap/Depr(5y)N/A
Cap/Sales(3y)3.53%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-17.68%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%39.77%
EPS Next Y6.67%
EPS Next 2Y110.16%
EPS Next 3Y100.83%
EPS Next 5YN/A
Revenue 1Y (TTM)18.92%
Revenue growth 3Y14.58%
Revenue growth 5Y41.99%
Sales Q2Q%63.39%
Revenue Next Year528.03%
Revenue Next 2Y557.52%
Revenue Next 3Y334.01%
Revenue Next 5YN/A
EBIT growth 1Y-8.18%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-72.25%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-71.4%
OCF growth 3YN/A
OCF growth 5YN/A